Is Protalix Biotherapeutics Stock a Good Investment?
Protalix Biotherapeutics Investment Advice | PLX |
- Examine Protalix Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Protalix Biotherapeutics' leadership team and their track record. Good management can help Protalix Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Protalix Biotherapeutics' business and its evolving consumer preferences.
- Compare Protalix Biotherapeutics' performance and market position to its competitors. Analyze how Protalix Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Protalix Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Protalix Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Protalix Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Protalix Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Protalix Biotherapeutics Stock
Researching Protalix Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 0.58. The company last dividend was issued on the 20th of December 2019. Protalix Biotherapeutics had 1:10 split on the 20th of December 2019.
To determine if Protalix Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protalix Biotherapeutics' research are outlined below:
| Protalix Biotherapeutics generated a negative expected return over the last 90 days | |
| Protalix Biotherapeutics has high historical volatility and very poor performance | |
| Protalix Biotherapeutics may become a speculative penny stock |
Protalix Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Protalix Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protalix Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Protalix Biotherapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 115.43 M.Protalix Biotherapeutics' profitablity analysis
The company has Net Profit Margin of 0.07 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (0.41) %, which entails that for every $100 of revenue, it lost $0.41.Determining Protalix Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Protalix Biotherapeutics is a good buy. For example, gross profit margin measures Protalix Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Protalix Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Check Protalix Biotherapeutics' Beneish M Score to see the likelihood of Protalix Biotherapeutics' management manipulating its earnings.
Basic technical analysis of Protalix Stock
As of the 21st of July, Protalix Biotherapeutics holds the Coefficient Of Variation of (1,171), variance of 47.16, and Risk Adjusted Performance of (0.07). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them.Protalix Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protalix Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protalix Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protalix Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protalix Biotherapeutics' Outstanding Corporate Bonds
Protalix Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protalix Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protalix bonds can be classified according to their maturity, which is the date when Protalix Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Understand Protalix Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Protalix Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.89 | |||
| Coefficient Of Variation | (1,171) | |||
| Standard Deviation | 6.87 | |||
| Variance | 47.16 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.60) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 53.03 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 6.21 | |||
| Skewness | (3.00) | |||
| Kurtosis | 18.41 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.89 | |||
| Coefficient Of Variation | (1,171) | |||
| Standard Deviation | 6.87 | |||
| Variance | 47.16 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.60) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 53.03 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 6.21 | |||
| Skewness | (3.00) | |||
| Kurtosis | 18.41 |
Consider Protalix Biotherapeutics' intraday indicators
Protalix Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protalix Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 56003.82 | |||
| Daily Balance Of Power | 0.6364 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 1.55 | |||
| Day Typical Price | 1.54 | |||
| Price Action Indicator | 0.01 | |||
| Period Momentum Indicator | 0.07 |
Protalix Stock media impact
There is far too much social signal, news, headlines, and media speculation about Protalix Biotherapeutics that are available to investors today. This information is accessible both publicly - through Protalix Biotherapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Protalix-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Protalix Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protalix Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protalix Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protalix Biotherapeutics alpha.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.